Multiple endocrine neoplasia type 1 epidemiology and demographics

	Multiple endocrine neoplasia type 1 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 1 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Multiple endocrine neoplasia type 1 epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple endocrine neoplasia type 1 epidemiology and demographics
CDC on Multiple endocrine neoplasia type 1 epidemiology and demographics
Multiple endocrine neoplasia type 1 epidemiology and demographics in the news
Blogs on Multiple endocrine neoplasia type 1 epidemiology and demographics
Directions to Hospitals Treating Multiple endocrine neoplasia type 1
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

- Worldwide, the prevalence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average prevalence of _____ per 100,000 persons.
- In developed countries, the prevalence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average prevalence of _____ per 100,000 persons.
- In developed countries, the prevalence of (insert disease state here) is _____ per 100,000 persons.

- Worldwide, the incidence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
- In developed countries, the incidence of (insert disease state here) is _____ per 100,000 persons.
- In developing countries/ Africa, the incidence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.

Endocrine and non-endocrine manifestations of the disease in MEN1 patients most often begin in the fourth or fifth decade. The onset of the disease is rare before age 10 years.

The prevalence and incidence of (insert disease state here) does not vary by gender.
Men and women are affected equally by (insert disease name here).
(Insert disease state here) is more prevalent in men women.
The prevalence of (insert disease state here) among men is ____ per 100,000, while it is _____ per 100,000 among women.
The incidence of (insert disease state here) among men is ____ per 100,000, while it is _____ per 100,000 among women.

In this section you should describe the impact of the disease in developed countries.
Incidence, prevalence, and geographical distribution or areas of interest can be mentioned, as well as the impact the disease has on society.
For an example of a developed countries section in an epidemiology and demographics page, click here.

In this section you should describe the impact of the disease in developing countries.
Incidence, prevalence, and geographical distribution or areas of interest can be mentioned, as well as the impact the disease has on society.
For an example of a developing countries section in an epidemiology and demographics page, click here.